Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

NCT03588936 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Poor accrual and loss of funding.

Conditions

Acute Leukemia
Chronic Leukemia
Lymphoma
Myelodysplastic Syndromes

Interventions

DRUG: Nivolumab (.25 mg/kg)
DRUG: Tocilizumab
DRUG: Nivolumab (.5 mg/kg)

Sponsor

Medical College of Wisconsin